$3.73
9.69%
Nasdaq, Oct 15, 03:01 pm EDT. Market open.
ISIN
US19516Q2084
Symbol
CLGN

Collplant Holdings ADR Stock price

$4.13
+0.64 18.34% 1M
+1.20 40.81% 6M
-9.87 70.50% YTD
-19.07 82.20% 1Y
-47.37 91.98% 3Y
-159.27 97.47% 5Y
-174.82 97.69% 10Y
-180.52 97.76% 20Y
Nasdaq, Closing price Wed, Oct 14 2026
+0.22 5.63%
ISIN
US19516Q2084
Symbol
CLGN
Industry

Is Collplant Holdings ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.

Key metrics

Basic
Market capitalization
$7.8m
Enterprise Value
$3.6m
Net debt
positive
Cash
$4.3m
Shares outstanding
1.4m
Valuation
P/E
negative
P/S | estimate
20.0 | 1.0
EV/Sales | estimate
9.1 | 0.4
EV/FCF | ex SBC
negative | negative
P/B
1.6
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
-192.1%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$800.0k | 205.1%
SBC as % of FCF
-
SBC Growth 1Y
-55.8%
Share Count Growth 1Y
-87.4%
Shareholder Yield
87.4%
Financials
Revenue | estimate
$390.0k | $8.1m
EBITDA
$-12.1m
EBIT
$-13.0m
Net Income
$-13.1m
Free Cash Flow | ex SBC
$-11.3m | $-12.1m
Growth
Revenue | estimate
-84.2% | 240.6%
EBITDA
11.1%
EBIT
11.1%
Net Income
5.3%
Free Cash Flow
8.8%
Margin
Gross
-147.6%
EBITDA
-3,103.3%
EBIT
-3,329.1%
Net
-3,376.4%
Free Cash Flow | ex SBC
-2,911.6% | -3,117.5%
More
EPS
$-9.6
FCF per Share
$-7.9
Short interest
2.8%
Employees
39
Rev per Employee
$60.0k

Collplant Holdings ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Collplant Holdings ADR forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Collplant Holdings ADR forecast:

Buy
86%
Hold
14%

Collplant Holdings ADR Events

Past Events
SEP
17
Special Call - CollPlant Biotechnologies Ltd.
28 days ago

Financial data from Collplant Holdings ADR

Mar '26
+/-
%
0.39 0.39
84% 84%
100%
- Direct Costs 0.96 0.96
24% 24%
246%
-0.57 -0.57
148% 148%
-146%
- Selling and Administrative Expenses 4.62 4.62
17% 17%
1,185%
- Research and Development Expense 7.76 7.76
24% 24%
1,990%
-12 -12
11% 11%
-3,095%
- Depreciation and Amortization 0.88 0.88
12% 12%
226%
EBIT (Operating Income) EBIT -13 -13
11% 11%
-3,321%
Net Profit -13 -13
5% 5%
-3,367%

In millions USD.

Don't miss a Thing! We will send you all news about Collplant Holdings ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Collplant Holdings ADR Stock News

Neutral
PRNewsWire
●
6 days ago
Transaction Led Primarily by Existing Investors to Accelerate LightSolver's Laser-Based Supercomputing Development REHOVOT, Israel, Oct. 9, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), an innovative technology company operating at the intersection of deep-tech photonic computing and biotechnology  today announced that it has entered into definitive agreements for the issuance ...
Neutral
PRNewsWire
●
9 days ago
CollPlant Advances its Photonic Computing Strategy Through LightSolver's Growing IP Portfolio REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that its subsidiary, LightSolver, has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for an invention that significantly expands the capabilities of its ...
Neutral
PRNewsWire
●
15 days ago
Strategic Expansion into Photonic Computing via LightSolver Acquisition Diversifies Technology Portfolio Alongside Continued Innovations in Regenerative Medicine REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), today announced financial results for the second quarter of 2026 and provided a corporate update.
More Collplant Holdings ADR News

Company Profile

CollPlant Biotechnologies Ltd. is a regenerative medicine company, which engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. The company's products include VergenixSTR, VergenixFG, and CollPlant Surgical Matrix. The company was founded by Oded Shoseyov in June 2004 and is headquartered in Rehovot, Israel.

Head office Israel
CEO Mr. Tal
Employees 39
Founded 2004
Website www.collplant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today